IgA 신증(버거병) : 시장 전망

This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger's Disease) Therapeutics.

• In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData's epidemiology forecast.
• Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression.
• The Berger's disease pipeline holds 112 molecules, with three assets in the pre-registration stage, 16 assets in Phase III development, and 24 assets in Phase II development.
• Over the past decade, 282 clinical trials have been conducted in Berger's disease. The years with the most studies initiated were 2025, with 68 trials, followed by 2024, with 42 trials.
• Over the past decade, in deals involving companies developing Berger's disease products, licensing agreements accounted for the largest share of deals in North America (31.5%), Europe (48.3%), and APAC (68.5%). In South America and Africa, licensing agreements were the sole contributors (100%).
• The consensus from PMR is that there is a foundational role for RAS blockade and SGLT2 inhibitors, but significant variation exists around the timing of immunosuppression and the interpretation of biopsy-driven treatment decisions.

Scope

GlobalData's IgA nephropathy (Berger's Disease): Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule type
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the IgA Nephropathy (Berger's Disease) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global IgA Nephropathy (Berger's Disease)Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview of Drugs by Approval and Drug Type
• 4.3 Overview of Drugs by Molecule Type
• 4.4 Overview of Drugs by MOA
• 4.5 Product Profile and Sales Forecast

5 Unmet need

6 Pricing and Reimbursement Assessment

7 Pipeline Drugs Assessment

• 7.1 Pipeline Drugs
• 7.2 Overview by Development Stage
• 7.3 Overview by Mechanism of Action
• 7.4 Overview by Molecule Type
• 7.5 Product Profile and Sales Forecast
• 7.6 Drug-specific PTSR and LoA
• 7.7 Indication-specific and Therapy Area-specific PTSR and LoA

8 Clinical Trials Assessment

• 8.1 Historical Overview
• 8.2 Overview by Phase
• 8.3 Overview by Status
• 8.4 Overview by Phase for Ongoing and Planned Trials
• 8.5 Trials with Virtual Components
• 8.6 Top 20 Biomarkers by Trial Phase
• 8.7 Overview of Trials by Geography
• 8.8 Single-Country and Multinational Trials by Region
• 8.9 Top 20 Sponsors with Breakdown by Phase
• 8.10 Top 20 Sponsors with Breakdown by Status
• 8.11 Overview by Endpoint Status
• 8.12 Overview by Race and Ethnicity
• 8.13 Enrollment Data
• 8.14 Top 20 countries for Trial Sites
• 8.15 Top 20 Sites Globally
• 8.16 Feasibility Analysis - Geographic Overview
• 8.17 Feasibility Analysis - Benchmark Models

9 Deals Landscape

• 9.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 9.2 Recent Mergers, Acquisitions, and Strategic Alliances

10 Commercial Assessment

• 10.1 Key Market Players

11 Future Market Catalysts

12 Appendix

• 12.1 Methodology
• 12.2 Methodology - Sales Forecast
• 12.3 Methodology - Pricing and Reimbursement
• 12.4 Methodology - PTSR and LoA Analysis
• 12.5 About the Authors
• 12.6 Contact Us
• 12.7 Disclaimer